Indolizidine (-)-235B ' and related structural analogs: Discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [H-3]dopamine release

Department of Pharmaceutical Science, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA.
European journal of pharmacology (Impact Factor: 2.68). 02/2011; 658(2-3):132-9. DOI: 10.1016/j.ejphar.2011.02.018
Source: PubMed

ABSTRACT Although several therapeutic agents are available to aid in tobacco smoking cessation, relapse rates continue to be high, warranting the development of alternative pharmacotherapies. Nicotine-evoked dopamine release from its presynaptic terminals in the central nervous system leads to reward which maintains continued tobacco use. The ability of indolizidine (-)-235B' and a sub-library of structurally related analogs to inhibit nicotine-evoked [(3)H]dopamine release from rat striatal slices was determined in the current study. Indolizidine (-)-235B' inhibited nicotine-evoked [(3)H]dopamine release in a concentration-dependent manner (IC(50)=42 nM, I(max)=55%). Compound (-)-237D, the double bond-reduced analog, afforded the greatest inhibitory potency (IC(50)=0.18 nM, I(max)=76%), and was 233-fold more potent than indolizidine (-)-235B'. The des-8-methyl aza-analog of indolizidine (-)-235B', ZZ-272, also inhibited nicotine-evoked [(3)H]dopamine release (IC(50)=413 nM, I(max)=59%). Concomitant exposure to maximally effective concentrations of indolizidine (-)-235B', ZZ-272 or (-)-237D with a maximally effective concentration of α-conotoxin MII, a selective antagonist for α6β2-containing nicotinic receptors, resulted in inhibition of nicotine-evoked [(3)H]dopamine release no greater than that produced by each compound alone. The latter results suggest that indolizidine (-)-235B', (-)-237D, ZZ-272 and α-conotoxin MII inhibit the same α-conotoxin MII-sensitive nicotinic receptor subtypes. Thus, indolizidine (-)-235B' and its analogs act as antagonists of α6β2-nicotinic receptors and constitute a novel structural scaffold for the discovery of pharmacotherapies for smoking cessation.


Available from: Peter A Crooks, Jun 13, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Highly stereocontrolled total synthesis of dart frog indolizidine alkaloids (–)-167B, (–)-209I, and (–)-223A was accomplished, with a common tricyclic lactone intermediate as the starting compound, in overall yields of 17 %, 14 %, and 17 %, respectively. The C7–C8 bond of the 167B, without a C8 chiral substituent, was formed through ring closure metathesis followed by hydrogenation. In 209I and 223A, which have a C8 chiral substituent, highly substrate-controlled asymmetric radical cyclization was used to form the C7–C8 bond, and the correct stereochemistry of the C8 substituents was obtained in both molecules. Ethyl substituent at the C6 position of 223A was obtained with correct stereochemistry through asymmetric alkylation/epimerization sequences of the tricyclic lactone. Cleavage of the excess carbon on the C5 position of all three indolizidines was performed by using a Barton decarboxylation protocol. Reduction of the corresponding indolizidin-3-ones by LAH completed the total synthesis of (–)-167B, (–)-209I and (–)-223A.
    European Journal of Organic Chemistry 02/2015; 2015(8). DOI:10.1002/ejoc.201500028 · 3.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: (+)-Laburnamine (1), a rare alkaloid extracted from Laburnum anagyroides seeds (∼4 mg from 1 kg), was shown to bind with high affinity (Ki, 293 nM) to the α4β2 nicotinic receptor subtype, which is, respectively, 126 and 136 times higher than to the α3β4 (Ki 37 μM) and α7 subtypes (Ki 40 μM). When its ability to release [3H]-dopamine from striatal slices was tested in a functional assay, compound 1 behaved as a partial agonist with an EC50 of 5.8 μM and an Emax that was 43% that of nicotine. When incubated with nicotine in the same assay, 1 prevented a maximal effect from being reached.
    Journal of Natural Products 03/2013; 76(4). DOI:10.1021/np3007028 · 3.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sixteen indolizidine-based alkaloids (IBAs) that were isolated as poison constituents of the skin of frogs were synthesized in a highly flexible and stereoselective manner. As a key step, a three-component, organocatalytic, highly enantio- and diastereoselective vinylogous Mukaiyama-Mannich reaction was employed furnishing optically highly enriched butyrolactams as central intermediates on a multigram scale. The attached six-membered ring was constructed through cyclization of the pendant enoate moiety onto the pyrrolidine ring. The absolute configuration of the bridgehead chiral center and the adjacent 8-position was established in the initial vinylogous Mannich reaction, whereas the 3- and 5-substituents were introduced through organometallic addition at a late stage of the synthesis with full stereochemical control from the substrate. With this strategy, simple as well as even more complex alkaloids were accessible in good overall yields as single stereoisomers. These syntheses also served to establish the absolute and relative configuration of those IBAs that had never been synthesized before.
    Chemistry - A European Journal 02/2014; 20(7). DOI:10.1002/chem.201304086 · 5.70 Impact Factor